Adolor's Entereg "Approvable"; Ongoing Study May Provide Confirmatory Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is requesting that the company confirm efficacy of the postoperative ileus therapy. An ongoing Phase III trial with Entereg could address FDA's concerns.
You may also be interested in...
Adolor Disbands Entereg Sales Force Following Second 'Approvable' Letter
Firm plans to submit complete response to FDA in Q2 2007.
Adolor Disbands Entereg Sales Force Following Second 'Approvable' Letter
Firm plans to submit complete response to FDA in Q2 2007.
GSK/Adolor Entereg “Approvable” Pending CV Risk Data
FDA’s second “approvable” letter for the postoperative ileus treatment requests development of a risk management plan and 12-month safety data from an ongoing trial.